董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| John O. Agwunobi | 男 | Director | 52 | 24.50万美元 | 未持股 | 2017-04-12 |
| Perry G. Fine | 男 | Director | 64 | 24.00万美元 | 未持股 | 2017-04-12 |
| G. Scott MacKenzie | 男 | Director | 53 | 12.06万美元 | 未持股 | 2017-04-12 |
| Michael S. Diament | 男 | Director | 48 | 27.50万美元 | 未持股 | 2017-04-12 |
| William J. McBride | 男 | Director | 72 | 27.00万美元 | 未持股 | 2017-04-12 |
| Eran Broshy | 男 | Director | 58 | 26.75万美元 | 未持股 | 2017-04-12 |
| Kay Coles James | 女 | Director | 67 | 24.00万美元 | 未持股 | 2017-04-12 |
| Mary F. Sammons | 女 | Director | 70 | 26.00万美元 | 未持股 | 2017-04-12 |
| Barry M. Smith | 男 | Chairman and chief executive officer | 63 | 745.14万美元 | 未持股 | 2017-04-12 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Sam K. Srivastava | 男 | Chief Executive Officer, Magellan Healthcare | 49 | 265.69万美元 | 未持股 | 2017-04-12 |
| Mostafa M. Kamal | 男 | Chief Executive Officer, Magellan Rx Management | 36 | 177.18万美元 | 未持股 | 2017-04-12 |
| Jonathan N. Rubin | 男 | Chief Financial Officer | 53 | 236.61万美元 | 未持股 | 2017-04-12 |
| Daniel N. Gregoire | 男 | General Counsel and Secretary | 61 | 148.81万美元 | 未持股 | 2017-04-12 |
| Caskie Lewis Clapper | 女 | Chief Human Resources Officer | 52 | 114.75万美元 | 未持股 | 2017-04-12 |
| Barry M. Smith | 男 | Chairman and chief executive officer | 63 | 745.14万美元 | 未持股 | 2017-04-12 |
董事简历
中英对照 | 中文 | 英文- John O. Agwunobi
-
John O. Agwunobi，曾在Bluebird Bio, Inc.任职。自2017年起担任董事会成员。从2020年到2022年，他担任Herbalife Nutrition Inc.的首席执行官兼董事会主席。此前，Agwunobi博士于2018年5月至2020年担任Herbalife Nutrition Inc.联合总裁。他还担任Herbalife Nutrition Inc.的首席健康和营养官，负责培训、教育、科学战略和产品开发（2016年至2018年）。在加入Herbalife Nutrition Inc.之前，Agwunobi博士是一名独立顾问，为一些私人持有的健康相关公司提供咨询，包括代表私募股权公司Sun Capital Partners担任Shopko Stores Operating Co.， LLC的顾问委员会成员。从2007年9月到2014年4月，他担任美国沃尔玛（纽约证券交易所代码：WMT）的高级副总裁兼健康和保健总裁，在那里他发展了业务，并就公司的健康改革立场提供了见解和建议。2005年12月至2007年9月，他担任美国卫生与公众服务部助理卫生部长，负责疾病预防和健康促进。他的职责包括监督疾病控制中心、国家卫生研究所、美国食品和药物管理局、美国外科医生办公室以及许多其他公共卫生办公室和项目。Agwunobi博士还担任the Ensign Group, Inc.和the U.S. African Development Foundation的董事会成员。
John O. Agwunobi,has served on Bluebird Bio, Inc. Board since 2017. He was Chief Executive Officer and Chairman of the Board of Herbalife Nutrition Inc. from 2020 to 2022. Previously, Dr. Agwunobi served as Co-President of Herbalife from May 2018 to 2020. He also served as Chief Health and Nutrition Officer at Herbalife, responsible for training, education, science strategy and product development from 2016 to 2018. Prior to joining Herbalife, Dr. Agwunobi was an independent consultant, advising a number of privately-held health-related companies, including serving as an advisory board member of Shopko Stores Operating Co., LLC on behalf of the private equity firm Sun Capital Partners. From September 2007 to April 2014, Dr. Agwunobi served as Senior Vice President and President of Health and Wellness for Wal-Mart (NYSE: WMT) in the United States where he grew the business and provided insight and advice on the company's health reform position. From December 2005 to September 2007, he served as the Assistant Secretary of Health for the U.S. Department of Health and Human Services, where he was responsible for disease prevention and health promotion. His responsibilities included the oversight of the Centers for Disease Control, National Institute of Health, the U.S. Food and Drug Administration, the Office of the U.S. Surgeon General, and numerous other public health offices and programs. Dr. Agwunobi also serves on the Board of the Ensign Group, Inc. and the Board of the U.S. African Development Foundation. - John O. Agwunobi，曾在Bluebird Bio, Inc.任职。自2017年起担任董事会成员。从2020年到2022年，他担任Herbalife Nutrition Inc.的首席执行官兼董事会主席。此前，Agwunobi博士于2018年5月至2020年担任Herbalife Nutrition Inc.联合总裁。他还担任Herbalife Nutrition Inc.的首席健康和营养官，负责培训、教育、科学战略和产品开发（2016年至2018年）。在加入Herbalife Nutrition Inc.之前，Agwunobi博士是一名独立顾问，为一些私人持有的健康相关公司提供咨询，包括代表私募股权公司Sun Capital Partners担任Shopko Stores Operating Co.， LLC的顾问委员会成员。从2007年9月到2014年4月，他担任美国沃尔玛（纽约证券交易所代码：WMT）的高级副总裁兼健康和保健总裁，在那里他发展了业务，并就公司的健康改革立场提供了见解和建议。2005年12月至2007年9月，他担任美国卫生与公众服务部助理卫生部长，负责疾病预防和健康促进。他的职责包括监督疾病控制中心、国家卫生研究所、美国食品和药物管理局、美国外科医生办公室以及许多其他公共卫生办公室和项目。Agwunobi博士还担任the Ensign Group, Inc.和the U.S. African Development Foundation的董事会成员。
- John O. Agwunobi,has served on Bluebird Bio, Inc. Board since 2017. He was Chief Executive Officer and Chairman of the Board of Herbalife Nutrition Inc. from 2020 to 2022. Previously, Dr. Agwunobi served as Co-President of Herbalife from May 2018 to 2020. He also served as Chief Health and Nutrition Officer at Herbalife, responsible for training, education, science strategy and product development from 2016 to 2018. Prior to joining Herbalife, Dr. Agwunobi was an independent consultant, advising a number of privately-held health-related companies, including serving as an advisory board member of Shopko Stores Operating Co., LLC on behalf of the private equity firm Sun Capital Partners. From September 2007 to April 2014, Dr. Agwunobi served as Senior Vice President and President of Health and Wellness for Wal-Mart (NYSE: WMT) in the United States where he grew the business and provided insight and advice on the company's health reform position. From December 2005 to September 2007, he served as the Assistant Secretary of Health for the U.S. Department of Health and Human Services, where he was responsible for disease prevention and health promotion. His responsibilities included the oversight of the Centers for Disease Control, National Institute of Health, the U.S. Food and Drug Administration, the Office of the U.S. Surgeon General, and numerous other public health offices and programs. Dr. Agwunobi also serves on the Board of the Ensign Group, Inc. and the Board of the U.S. African Development Foundation.
- Perry G. Fine
-
Perry G. Fine， 他于2014年第一次当选董事。他是犹他大学医学院（the School of Medicine at the University of Utah）的麻醉学教授，在那里他任教于疼痛研究中心，并是疼痛管理中心的主治医生。他是Capital Caring（位于华盛顿特区）的国家战略顾问，发展社区环境下的高级疾病护理协调的可持续发展模式，作为综合高级疾病护理的综合组件。他目前任职于Ossipee Lake Alliance（一个非盈利环保组织）、ISA Scientific（民营初创生物技术制药开发公司）的董事会。
Perry G. Fine, M.D. was first elected to the board in 2014. Dr. Fine is a professor in the Department of Anesthesiology of the School of Medicine at the University of Utah, where he serves on the faculty in the Pain Research Center, and is an attending physician in the Pain Management Center. He currently serves on the boards of directors of Ossipee Lake Alliance, a non-profit environmental organization, and Anne Stirba Cancer Foundation, a non-profit organization dedicated to fundraising for breast cancer research. He is past president of the American Academy of Pain Medicine. - Perry G. Fine， 他于2014年第一次当选董事。他是犹他大学医学院（the School of Medicine at the University of Utah）的麻醉学教授，在那里他任教于疼痛研究中心，并是疼痛管理中心的主治医生。他是Capital Caring（位于华盛顿特区）的国家战略顾问，发展社区环境下的高级疾病护理协调的可持续发展模式，作为综合高级疾病护理的综合组件。他目前任职于Ossipee Lake Alliance（一个非盈利环保组织）、ISA Scientific（民营初创生物技术制药开发公司）的董事会。
- Perry G. Fine, M.D. was first elected to the board in 2014. Dr. Fine is a professor in the Department of Anesthesiology of the School of Medicine at the University of Utah, where he serves on the faculty in the Pain Research Center, and is an attending physician in the Pain Management Center. He currently serves on the boards of directors of Ossipee Lake Alliance, a non-profit environmental organization, and Anne Stirba Cancer Foundation, a non-profit organization dedicated to fundraising for breast cancer research. He is past president of the American Academy of Pain Medicine.
- G. Scott MacKenzie
-
G.Scott MacKenzie于2016年11月首次被任命为董事会成员，并在年度会议上首次被提名选举。他目前担任M*Modal，Inc.（私人持有的临床文档服务和技术公司）的首席执行官（2014年以来）。他此前曾担任Experian Health公司的首席执行官（2013年至2014年），以及Passport Health Communications公司的首席执行官（2009年至2014年）。麦肯齐先生是Medhost，Inc.（一家私人持有的梦百合金融软件开发商）的董事会成员，并一直担任Invision Heart，Inc.（一家私人持有的心脏护理解决方案公司）的董事会成员，直到2017年3月。
G. Scott MacKenzie was first appointed to the board in November 2016 and is nominated for election for the first time at the annual meeting. He currently serves as the chief executive officer of M*Modal, Inc., a privately held clinical documentation service and technology company, a position which he has held since 2014. He previously served as the chief executive officer of Experian Health from 2013 to 2014 and as chief executive officer of Passport Health Communications from 2009 to 2014. Mr. MacKenzie serves on the board of directors of MedHost, Inc., a privately-held developer of healthcare financial software, and until March 2017 served on the board of directors of Invision Heart, Inc., a privately-held cardiac care solutions company. - G.Scott MacKenzie于2016年11月首次被任命为董事会成员，并在年度会议上首次被提名选举。他目前担任M*Modal，Inc.（私人持有的临床文档服务和技术公司）的首席执行官（2014年以来）。他此前曾担任Experian Health公司的首席执行官（2013年至2014年），以及Passport Health Communications公司的首席执行官（2009年至2014年）。麦肯齐先生是Medhost，Inc.（一家私人持有的梦百合金融软件开发商）的董事会成员，并一直担任Invision Heart，Inc.（一家私人持有的心脏护理解决方案公司）的董事会成员，直到2017年3月。
- G. Scott MacKenzie was first appointed to the board in November 2016 and is nominated for election for the first time at the annual meeting. He currently serves as the chief executive officer of M*Modal, Inc., a privately held clinical documentation service and technology company, a position which he has held since 2014. He previously served as the chief executive officer of Experian Health from 2013 to 2014 and as chief executive officer of Passport Health Communications from 2009 to 2014. Mr. MacKenzie serves on the board of directors of MedHost, Inc., a privately-held developer of healthcare financial software, and until March 2017 served on the board of directors of Invision Heart, Inc., a privately-held cardiac care solutions company.
- Michael S. Diament
-
Michael S. Diamentt在2004年第一次被任命为董事。从2001年1月至2006年2月他曾担任投资管理公司的投资组合经理、破产和重组投资顾问。从2000年2月到2001年1月他是Sandell Asset Management（投资管理公司）的一位高级分析师， 从1998年7月到2000年1月担任Havens Advisors（投资管理公司）副总裁。他目前是Dayco, LLC的董事，公司前身Mark IV Industries, Inc（一家引擎技术解决方案的民营制造商）和USEC Inc.（纽约证券交易所交易浓缩铀加工和供应的公司）。并在此前的5年中，他曾在Journal Register Company（一家多平台的本地新闻和信息民营公司）和J.L. French Automotive Castings, Inc（一家民营汽车零部件公司）的董事会工作。
Michael S. Diament was first appointed to the board in 2004 and was elected for the first time in 2007. He formerly served as portfolio manager and director of bankruptcies and restructurings from January 2001 to February 2006 for Q Investments, an investment management firm. He currently serves on the board of directors of Centrus Energy formerly named USEC Inc., a New York Stock Exchange-traded enriched uranium supply company, and through August 2016 served as chairman and on the board of directors of Dayco, LLC (formerly named Mark IV Industries, Inc.), a privately-held manufacturer of engine technology solutions. - Michael S. Diamentt在2004年第一次被任命为董事。从2001年1月至2006年2月他曾担任投资管理公司的投资组合经理、破产和重组投资顾问。从2000年2月到2001年1月他是Sandell Asset Management（投资管理公司）的一位高级分析师， 从1998年7月到2000年1月担任Havens Advisors（投资管理公司）副总裁。他目前是Dayco, LLC的董事，公司前身Mark IV Industries, Inc（一家引擎技术解决方案的民营制造商）和USEC Inc.（纽约证券交易所交易浓缩铀加工和供应的公司）。并在此前的5年中，他曾在Journal Register Company（一家多平台的本地新闻和信息民营公司）和J.L. French Automotive Castings, Inc（一家民营汽车零部件公司）的董事会工作。
- Michael S. Diament was first appointed to the board in 2004 and was elected for the first time in 2007. He formerly served as portfolio manager and director of bankruptcies and restructurings from January 2001 to February 2006 for Q Investments, an investment management firm. He currently serves on the board of directors of Centrus Energy formerly named USEC Inc., a New York Stock Exchange-traded enriched uranium supply company, and through August 2016 served as chairman and on the board of directors of Dayco, LLC (formerly named Mark IV Industries, Inc.), a privately-held manufacturer of engine technology solutions.
- William J. McBride
-
William J. McBride在2004年第一次被任命为董事，并于近期退休了。1995年退休前，他在Value Health, Inc.（ 纽约证券交易所上市的专业管理式医疗保健公司，其中包括价值行为健康行为健康最大化管理式医疗公司之一）担任董事。他从1987年到1995年担任Value Health, Inc.的总裁兼首席运营官，负责所有公司及其子公司的经营活动。在加入Value Health之前，他花了15年在INA Corporation和它的继承者CIGNA Corporation中担任各种职位，包括CIGNA Healthplan, Inc.的总裁兼首席执行官，他目前是Internet HealthCare Group（早期医疗技术风险基金）董事， Women's Health USA, Inc（一家民营医疗服务公司）。他以前在Amerigroup Corporation（一个健康保险上市公司）董事会任职。
William J. McBride was first appointed to the board in 2004 and was elected for the first time in 2008. Mr. McBride is currently retired. Prior to his retirement in 1995 Mr. McBride was a director of Value Health, Inc., a New York Stock Exchange-listed specialty managed-care company, which included Value Behavioral Health, one of the largest behavioral health managed care companies at the time. From 1987 to 1995 Mr. McBride served as president and chief operating officer of Value Health, Inc., overseeing all operational activities of the company and its subsidiaries. Prior to his tenure at Value Health, Mr. McBride spent 15 years in a variety of positions with INA Corporation and its successor, Cigna Corporation, including serving as president and chief executive officer of Cigna Healthplan, Inc. Mr. McBride currently serves on the board of directors of Women's Health USA, Inc., a privately-held healthcare services company, and Internet Healthcare Group, LLC, a venture capital group. He previously served on the board of Amerigroup Corporation, which was previously a publicly-traded health insurance company. - William J. McBride在2004年第一次被任命为董事，并于近期退休了。1995年退休前，他在Value Health, Inc.（ 纽约证券交易所上市的专业管理式医疗保健公司，其中包括价值行为健康行为健康最大化管理式医疗公司之一）担任董事。他从1987年到1995年担任Value Health, Inc.的总裁兼首席运营官，负责所有公司及其子公司的经营活动。在加入Value Health之前，他花了15年在INA Corporation和它的继承者CIGNA Corporation中担任各种职位，包括CIGNA Healthplan, Inc.的总裁兼首席执行官，他目前是Internet HealthCare Group（早期医疗技术风险基金）董事， Women's Health USA, Inc（一家民营医疗服务公司）。他以前在Amerigroup Corporation（一个健康保险上市公司）董事会任职。
- William J. McBride was first appointed to the board in 2004 and was elected for the first time in 2008. Mr. McBride is currently retired. Prior to his retirement in 1995 Mr. McBride was a director of Value Health, Inc., a New York Stock Exchange-listed specialty managed-care company, which included Value Behavioral Health, one of the largest behavioral health managed care companies at the time. From 1987 to 1995 Mr. McBride served as president and chief operating officer of Value Health, Inc., overseeing all operational activities of the company and its subsidiaries. Prior to his tenure at Value Health, Mr. McBride spent 15 years in a variety of positions with INA Corporation and its successor, Cigna Corporation, including serving as president and chief executive officer of Cigna Healthplan, Inc. Mr. McBride currently serves on the board of directors of Women's Health USA, Inc., a privately-held healthcare services company, and Internet Healthcare Group, LLC, a venture capital group. He previously served on the board of Amerigroup Corporation, which was previously a publicly-traded health insurance company.
- Eran Broshy
-
Eran Broshy在2009年首次当选为董事，在2009年2月被任命为董事长。他目前是Linden Capital Partners的一个管理者，并成为Court Square Capital的资本顾问，这两个是私人股本公司。他之前担任Providence Equity LLC（一家私人股本公司）的高级顾问。十多年来他担任inVentiv Health, Inc. （一家民营企业直到2010年8月在纳斯达克上市成为提供了一个广泛的定制的临床、通信、商业和病人的结果解决制药和生命科学公司）的首席执行官和董事会主席。加入inVentiv之前，他在The Boston Consulting Group （"BCG"）工作了14年并负责整个美洲BCG的医疗实践。他还担任Coelacanth Corporation（一家民营生物技术公司）的总裁兼首席执行官。之前五年内他在inVentiv Health, Inc.、Virtual Radiologic Corporation（一个私人teleradiology公司）、ikaSystems Corporation（一个私人支付企业软件公司）、 HeartFlow一个私人基因检测公司、Correlagen Diagnostics（神经元质公司）、Neurogen Corporation（在纳斯达克上市的生物技术公司和工会街收购公司）、Union Street Acquisition Corp（纳斯达克上市空头公司）担任董事。他也在西蒙维森塔尔中心的纽约执行委员会、麻省理工学院（MIT） 担任科学顾问委员会，麻省理工学院大脑和认知科学访问委员会和麻省理工学院医学工程和科学研究访问委员会担任会长。
Eran Broshy has served as a director since June 2014. Mr. Broshy has been working since June 2009 with multiple private equity firms supporting their healthcare investment efforts and on the board of select portfolio companies, including with Nordic Capital July 2016 - present, Tailwind Capital (Sep 2015 - present), Linden Capital Partners (March 2013 - August 2015), Court Square Capital (March 2013 - August 2015), and Providence Equity Partners (June 2009 - December 2012). Mr. Broshy previously served for over a decade as the chief executive officer (until 2008) and chairman of the board of directors (until 2010) of inVentiv Health, Inc., a privately held company (and until August 2010 a Nasdaq listed company) that delivers a broad range of clinical and commercialization services to pharmaceutical and life sciences companies globally. Prior to joining inVentiv, Mr. Broshy was a management consultant with The Boston Consulting Group (BCG) for 14 years, including as the partner responsible for BCG's healthcare practice across the Americas. He also served as president and chief executive officer of Coelacanth Corporation, a privately held biotechnology company. Within the previous five years Mr. Broshy has also served on the board of directors of Magellan Health. He currently also serves as chairman of the board of ERT and of DermaRite, both privately-held healthcare companies, as a member of the Corporation of the Massachusetts Institute of Technology ("MIT"), as chairman of the American Friends of the Open University of Israel, and on the board of governors of the American Jewish Committee. Mr. Broshy holds an M.B.A. from Harvard University, an M.S. in civil engineering from Stanford University, and a B.S. in civil engineering from the Massachusetts Institute of Technology. - Eran Broshy在2009年首次当选为董事，在2009年2月被任命为董事长。他目前是Linden Capital Partners的一个管理者，并成为Court Square Capital的资本顾问，这两个是私人股本公司。他之前担任Providence Equity LLC（一家私人股本公司）的高级顾问。十多年来他担任inVentiv Health, Inc. （一家民营企业直到2010年8月在纳斯达克上市成为提供了一个广泛的定制的临床、通信、商业和病人的结果解决制药和生命科学公司）的首席执行官和董事会主席。加入inVentiv之前，他在The Boston Consulting Group （"BCG"）工作了14年并负责整个美洲BCG的医疗实践。他还担任Coelacanth Corporation（一家民营生物技术公司）的总裁兼首席执行官。之前五年内他在inVentiv Health, Inc.、Virtual Radiologic Corporation（一个私人teleradiology公司）、ikaSystems Corporation（一个私人支付企业软件公司）、 HeartFlow一个私人基因检测公司、Correlagen Diagnostics（神经元质公司）、Neurogen Corporation（在纳斯达克上市的生物技术公司和工会街收购公司）、Union Street Acquisition Corp（纳斯达克上市空头公司）担任董事。他也在西蒙维森塔尔中心的纽约执行委员会、麻省理工学院（MIT） 担任科学顾问委员会，麻省理工学院大脑和认知科学访问委员会和麻省理工学院医学工程和科学研究访问委员会担任会长。
- Eran Broshy has served as a director since June 2014. Mr. Broshy has been working since June 2009 with multiple private equity firms supporting their healthcare investment efforts and on the board of select portfolio companies, including with Nordic Capital July 2016 - present, Tailwind Capital (Sep 2015 - present), Linden Capital Partners (March 2013 - August 2015), Court Square Capital (March 2013 - August 2015), and Providence Equity Partners (June 2009 - December 2012). Mr. Broshy previously served for over a decade as the chief executive officer (until 2008) and chairman of the board of directors (until 2010) of inVentiv Health, Inc., a privately held company (and until August 2010 a Nasdaq listed company) that delivers a broad range of clinical and commercialization services to pharmaceutical and life sciences companies globally. Prior to joining inVentiv, Mr. Broshy was a management consultant with The Boston Consulting Group (BCG) for 14 years, including as the partner responsible for BCG's healthcare practice across the Americas. He also served as president and chief executive officer of Coelacanth Corporation, a privately held biotechnology company. Within the previous five years Mr. Broshy has also served on the board of directors of Magellan Health. He currently also serves as chairman of the board of ERT and of DermaRite, both privately-held healthcare companies, as a member of the Corporation of the Massachusetts Institute of Technology ("MIT"), as chairman of the American Friends of the Open University of Israel, and on the board of governors of the American Jewish Committee. Mr. Broshy holds an M.B.A. from Harvard University, an M.S. in civil engineering from Stanford University, and a B.S. in civil engineering from the Massachusetts Institute of Technology.
- Kay Coles James
-
Kay Coles James女士现任Gloucester Institute公司总裁及创始人，该公司是一家非营利性机构，主要从事训练和培养非裔美国居民社区领袖。从2001年到2006年，她曾担任美国人事管理局主管，当时她还是总统乔治·W·布什主要的人力资源顾问。她曾为J.C. Watts Companies公司前合伙人提供咨询服务。James女士拥有汉普顿大学研究生学位。
Kay Coles James was first appointed to the board in July 2014 and was elected for the first time in 2015. Ms. James is the president and founder of the Gloucester Institute, a non-profit organization focused on developing future leaders. From June 2001 to January 2005 Ms. James served as director of the U.S. Office of Personnel Management, where she was principal human resources advisor to President George W. Bush. She has also served as secretary of Health and Human Resources for the Commonwealth of Virginia, where she was responsible for Medicare and Medicaid programs; a senior fellow at The Heritage Foundation; and assistant secretary of the U.S. Department of Health and Human Services. She currently serves on the board of trustees of The Heritage Foundation, on the board of directors of The PNC Financial Services Group, Inc., and on the board of directors of Cancer Treatment Centers of America. - Kay Coles James女士现任Gloucester Institute公司总裁及创始人，该公司是一家非营利性机构，主要从事训练和培养非裔美国居民社区领袖。从2001年到2006年，她曾担任美国人事管理局主管，当时她还是总统乔治·W·布什主要的人力资源顾问。她曾为J.C. Watts Companies公司前合伙人提供咨询服务。James女士拥有汉普顿大学研究生学位。
- Kay Coles James was first appointed to the board in July 2014 and was elected for the first time in 2015. Ms. James is the president and founder of the Gloucester Institute, a non-profit organization focused on developing future leaders. From June 2001 to January 2005 Ms. James served as director of the U.S. Office of Personnel Management, where she was principal human resources advisor to President George W. Bush. She has also served as secretary of Health and Human Resources for the Commonwealth of Virginia, where she was responsible for Medicare and Medicaid programs; a senior fellow at The Heritage Foundation; and assistant secretary of the U.S. Department of Health and Human Services. She currently serves on the board of trustees of The Heritage Foundation, on the board of directors of The PNC Financial Services Group, Inc., and on the board of directors of Cancer Treatment Centers of America.
- Mary F. Sammons
-
Mary F. Sammons，她曾担任Rite Aid Corporation的董事会主席（直到2012年1月），也曾任职于Rite Aid公司的董事会（从1999年到2013年6月）。她曾担任Rite Aid公司的首席执行官（从2003年到2010年6月），也曾担任Rite Aid Corporation的总裁（从1999年12月到2008年9月）。她曾担任Fred Meyer Stores公司的总裁和首席执行官（从1998年1月到1999年12月），也曾担任Fred Meyer公司的多种高级职务（从1980年到1998年）。她是Magellan Health Services公司（专业卫生保健管理商）的董事。
Mary F. Sammons was first elected to the board in 2012 after being appointed to the board in July 2011. She is currently retired. She served as the chairman of the board of Rite Aid Corporation "Rite Aid" from 2008 until 2012 and served on the board of directors of Rite Aid from 1999 to June 2013. From 2003 until 2010 Ms. Sammons served as chief executive officer of Rite Aid. Ms. Sammons is a member of the board of directors and lead director of StanCorp Financial Group, Inc., a New York Stock Exchange-listed insurance and financial services company, until March 7 2016 when it was acquired by Meiji Yasuda, a Japanese insurance and financial institution. - Mary F. Sammons，她曾担任Rite Aid Corporation的董事会主席（直到2012年1月），也曾任职于Rite Aid公司的董事会（从1999年到2013年6月）。她曾担任Rite Aid公司的首席执行官（从2003年到2010年6月），也曾担任Rite Aid Corporation的总裁（从1999年12月到2008年9月）。她曾担任Fred Meyer Stores公司的总裁和首席执行官（从1998年1月到1999年12月），也曾担任Fred Meyer公司的多种高级职务（从1980年到1998年）。她是Magellan Health Services公司（专业卫生保健管理商）的董事。
- Mary F. Sammons was first elected to the board in 2012 after being appointed to the board in July 2011. She is currently retired. She served as the chairman of the board of Rite Aid Corporation "Rite Aid" from 2008 until 2012 and served on the board of directors of Rite Aid from 1999 to June 2013. From 2003 until 2010 Ms. Sammons served as chief executive officer of Rite Aid. Ms. Sammons is a member of the board of directors and lead director of StanCorp Financial Group, Inc., a New York Stock Exchange-listed insurance and financial services company, until March 7 2016 when it was acquired by Meiji Yasuda, a Japanese insurance and financial institution.
- Barry M. Smith
-
Barry M. Smith，他是董事会的成员（自2014年以来）。他目前任职董事会的薪酬委员会、提名及公司治理委员会、质量保证和合规委员会。他曾一直担任Magellan Health, Inc.（全国最大的行为健康服务供应商，一个领先的放射学收益管理服务、专业制药和处方管理服务的国家供应商）的主席兼首席执行官（2013年以来）。他曾创立VistaCare, Inc.（一个临终关怀服务的国家供应商），担任主席、总裁和首席执行官，也曾于2003年担任VistaCare公司的主席。1990年至1995年，他曾担任Value Rx, Inc.（全国最大的药房福利管理公司）的主席兼首席执行官。此前，他曾担任PCS Health Systems（药房福利管理公司）的运营副总裁。
Barry M. Smith,most recently served as Chairman and Chief Executive Officer of Magellan Health, Inc. (NASDAQ: MGLN), the nation's largest provider of behavioral health services and a leading national provider of radiology benefit management services, specialty pharmacy and prescription benefit management services, since 2013. He retired from Magellan at the end of 2019. He founded and served as Chairman, President and Chief Executive Officer of VistaCare, Inc., a national provider of hospice services, from 1996 to 2002, and he served as Chairman of VistaCare in 2003. From 1990 through 1995, Mr. Smith served as Chairman and Chief Executive Officer of Value Rx, Inc., which was then one of the country's largest pharmacy benefit management companies and, prior to that, served as vice president of operations for PCS Health Systems, also a pharmacy benefit management firm. - Barry M. Smith，他是董事会的成员（自2014年以来）。他目前任职董事会的薪酬委员会、提名及公司治理委员会、质量保证和合规委员会。他曾一直担任Magellan Health, Inc.（全国最大的行为健康服务供应商，一个领先的放射学收益管理服务、专业制药和处方管理服务的国家供应商）的主席兼首席执行官（2013年以来）。他曾创立VistaCare, Inc.（一个临终关怀服务的国家供应商），担任主席、总裁和首席执行官，也曾于2003年担任VistaCare公司的主席。1990年至1995年，他曾担任Value Rx, Inc.（全国最大的药房福利管理公司）的主席兼首席执行官。此前，他曾担任PCS Health Systems（药房福利管理公司）的运营副总裁。
- Barry M. Smith,most recently served as Chairman and Chief Executive Officer of Magellan Health, Inc. (NASDAQ: MGLN), the nation's largest provider of behavioral health services and a leading national provider of radiology benefit management services, specialty pharmacy and prescription benefit management services, since 2013. He retired from Magellan at the end of 2019. He founded and served as Chairman, President and Chief Executive Officer of VistaCare, Inc., a national provider of hospice services, from 1996 to 2002, and he served as Chairman of VistaCare in 2003. From 1990 through 1995, Mr. Smith served as Chairman and Chief Executive Officer of Value Rx, Inc., which was then one of the country's largest pharmacy benefit management companies and, prior to that, served as vice president of operations for PCS Health Systems, also a pharmacy benefit management firm.
高管简历
中英对照 | 中文 | 英文- Sam K. Srivastava
Sam K. Srivastava，曾担任Cigna Health公司的国家和高级部门总裁。加入Cigna公司之前，他曾担任UnitedHealth Group、HealthNet的执行领导职务。他目前任职于耶鲁大学公共卫生学院（the Yale School of Public Health）、Oliver Wyman的咨询委员会。
Sam K. Srivastava serves as our Chief Executive Officer of NeueHealth as of March 2021 previously serving as our enterprise Chief Operating Officer since September 2019. Prior to joining Bright Health, Mr. Srivastava served as Chief Executive Officer of Magellan HealthCare from September 2013 to December 2018. From October 2007 to September 2013 Mr. Srivastava served as Cigna Healthcare’s President of National and Senior Segments, and led strategy and business development for the United States. Prior to Cigna, he held various executive positions at UnitedHealth Group, Inc. and Health Net, Inc. from January 1995 to September 2005 and October 2005 to October 2007 respectively, and served as a management consultant developing risk-based delivery systems for providers, insurers and governments in the U.S. and Europe. Mr. Srivastava is the Chairman of the Yale School of Public Health Advisory Board and a director for the Recovery Centers of America.- Sam K. Srivastava，曾担任Cigna Health公司的国家和高级部门总裁。加入Cigna公司之前，他曾担任UnitedHealth Group、HealthNet的执行领导职务。他目前任职于耶鲁大学公共卫生学院（the Yale School of Public Health）、Oliver Wyman的咨询委员会。
- Sam K. Srivastava serves as our Chief Executive Officer of NeueHealth as of March 2021 previously serving as our enterprise Chief Operating Officer since September 2019. Prior to joining Bright Health, Mr. Srivastava served as Chief Executive Officer of Magellan HealthCare from September 2013 to December 2018. From October 2007 to September 2013 Mr. Srivastava served as Cigna Healthcare’s President of National and Senior Segments, and led strategy and business development for the United States. Prior to Cigna, he held various executive positions at UnitedHealth Group, Inc. and Health Net, Inc. from January 1995 to September 2005 and October 2005 to October 2007 respectively, and served as a management consultant developing risk-based delivery systems for providers, insurers and governments in the U.S. and Europe. Mr. Srivastava is the Chairman of the Yale School of Public Health Advisory Board and a director for the Recovery Centers of America.
- Mostafa M. Kamal
Mostafa M. Kamal，他曾担任Magellan Rx Management的专业制药业务高级覅总裁和总经理以及其承销业务总监。从2011年到2014年，他曾担任定价、承销和分析的副总裁。加入公司之前，他担任Medco Health Solutions, Inc.现Express Scripts的战略和分析主管。他目前担任the Pharmaceutical Care Management Association董事。
Mostafa M. Kamal previously served as senior vice president and general manager of Magellan Rx Management's specialty pharmacy business, as well as its chief underwriting officer. From 2011 to 2014 Mr. Kamal was vice president of pricing, underwriting and analytics. Before joining the company, he served as director of strategy and analytics at Medco Health Solutions, Inc. now known as Express Scripts. He currently serves as a director of the Pharmaceutical Care Management Association.- Mostafa M. Kamal，他曾担任Magellan Rx Management的专业制药业务高级覅总裁和总经理以及其承销业务总监。从2011年到2014年，他曾担任定价、承销和分析的副总裁。加入公司之前，他担任Medco Health Solutions, Inc.现Express Scripts的战略和分析主管。他目前担任the Pharmaceutical Care Management Association董事。
- Mostafa M. Kamal previously served as senior vice president and general manager of Magellan Rx Management's specialty pharmacy business, as well as its chief underwriting officer. From 2011 to 2014 Mr. Kamal was vice president of pricing, underwriting and analytics. Before joining the company, he served as director of strategy and analytics at Medco Health Solutions, Inc. now known as Express Scripts. He currently serves as a director of the Pharmaceutical Care Management Association.
- Jonathan N. Rubin
2008年9月Jonathan N. Rubin成为公司的首席财务官。在加入公司之前， 从2004年到2008年他担任Dental and Vision for CIGNA Healthcare的高级副总裁，HealthCare Division of CIGNA Healthcare（CIGNA最大的部门）的高级副总裁兼首席财务官。从1985年到2004年他曾在担任各种职位。
Jonathan N. Rubin,Prior to joining the company in 2008 Mr. Rubin served as senior vice president, Dental and Vision for Cigna Health and senior vice president and chief financial officer of the HealthCare Division of Cigna Healthcare, Cigna's largest division, from 2004 to 2008. He previously served in various capacities with Cigna from 1985 to 2004. He currently serves on the boards of directors of American School for the Deaf and Jewish Teen Learning Connections.- 2008年9月Jonathan N. Rubin成为公司的首席财务官。在加入公司之前， 从2004年到2008年他担任Dental and Vision for CIGNA Healthcare的高级副总裁，HealthCare Division of CIGNA Healthcare（CIGNA最大的部门）的高级副总裁兼首席财务官。从1985年到2004年他曾在担任各种职位。
- Jonathan N. Rubin,Prior to joining the company in 2008 Mr. Rubin served as senior vice president, Dental and Vision for Cigna Health and senior vice president and chief financial officer of the HealthCare Division of Cigna Healthcare, Cigna's largest division, from 2004 to 2008. He previously served in various capacities with Cigna from 1985 to 2004. He currently serves on the boards of directors of American School for the Deaf and Jewish Teen Learning Connections.
- Daniel N. Gregoire
Daniel N. Gregoire在2005年1月成为总法律顾问和秘书。从2000年到2004年他曾担任Oxford Health Plans, Inc（纽约证券交易所上市的管理式医疗公司）的执行副总裁、总法律顾问和秘书。加入牛津之前， 从1981年到2000年他是Sheehan Phinney Bass + Green PA（美国新罕布什尔州曼彻斯特的律师事务所）的一名律师和股东。
Daniel N. Gregoire,Prior to joining the company in 2005 Mr. Gregoire was executive vice president, general counsel and secretary of Oxford Health Plans, Inc., a New York Stock Exchange-listed managed care company, from 2000 to 2004. Prior to joining Oxford, Mr. Gregoire was an attorney and shareholder with Sheehan Phinney Bass & Green PA, a Manchester, New Hampshire-based law firm, from 1981 to 2000.- Daniel N. Gregoire在2005年1月成为总法律顾问和秘书。从2000年到2004年他曾担任Oxford Health Plans, Inc（纽约证券交易所上市的管理式医疗公司）的执行副总裁、总法律顾问和秘书。加入牛津之前， 从1981年到2000年他是Sheehan Phinney Bass + Green PA（美国新罕布什尔州曼彻斯特的律师事务所）的一名律师和股东。
- Daniel N. Gregoire,Prior to joining the company in 2005 Mr. Gregoire was executive vice president, general counsel and secretary of Oxford Health Plans, Inc., a New York Stock Exchange-listed managed care company, from 2000 to 2004. Prior to joining Oxford, Mr. Gregoire was an attorney and shareholder with Sheehan Phinney Bass & Green PA, a Manchester, New Hampshire-based law firm, from 1981 to 2000.
- Caskie Lewis Clapper
Caskie Lewis Clapper于2004年成为该公司的首席人力资源官。自从1999年加入该公司后她多次在人力资源方面担任高级职位。加入Magellan之前，她担任Helix Health（一个位于Baltimore, Maryland的医疗系统）的人力资源职位。加入Helix之前，她在General Physics Corporation工作，在那里她负责员工与客户顾问工作并跨多个行业学习、组织发展和改进计划。
Caskie Lewis Clapper has held several senior positions in human resources since joining the company in 1999. Prior to joining Magellan, Ms. Lewis-Clapper served as Human Resources Operations lead for Helix Health, a Baltimore, Maryland-based health care system. Prior to joining Helix, she was with General Physics Corporation, where as a staff consultant she worked with clients across several industries on learning, organizational development and performance improvement initiatives.- Caskie Lewis Clapper于2004年成为该公司的首席人力资源官。自从1999年加入该公司后她多次在人力资源方面担任高级职位。加入Magellan之前，她担任Helix Health（一个位于Baltimore, Maryland的医疗系统）的人力资源职位。加入Helix之前，她在General Physics Corporation工作，在那里她负责员工与客户顾问工作并跨多个行业学习、组织发展和改进计划。
- Caskie Lewis Clapper has held several senior positions in human resources since joining the company in 1999. Prior to joining Magellan, Ms. Lewis-Clapper served as Human Resources Operations lead for Helix Health, a Baltimore, Maryland-based health care system. Prior to joining Helix, she was with General Physics Corporation, where as a staff consultant she worked with clients across several industries on learning, organizational development and performance improvement initiatives.
- Barry M. Smith
Barry M. Smith，他是董事会的成员（自2014年以来）。他目前任职董事会的薪酬委员会、提名及公司治理委员会、质量保证和合规委员会。他曾一直担任Magellan Health, Inc.（全国最大的行为健康服务供应商，一个领先的放射学收益管理服务、专业制药和处方管理服务的国家供应商）的主席兼首席执行官（2013年以来）。他曾创立VistaCare, Inc.（一个临终关怀服务的国家供应商），担任主席、总裁和首席执行官，也曾于2003年担任VistaCare公司的主席。1990年至1995年，他曾担任Value Rx, Inc.（全国最大的药房福利管理公司）的主席兼首席执行官。此前，他曾担任PCS Health Systems（药房福利管理公司）的运营副总裁。
Barry M. Smith,most recently served as Chairman and Chief Executive Officer of Magellan Health, Inc. (NASDAQ: MGLN), the nation's largest provider of behavioral health services and a leading national provider of radiology benefit management services, specialty pharmacy and prescription benefit management services, since 2013. He retired from Magellan at the end of 2019. He founded and served as Chairman, President and Chief Executive Officer of VistaCare, Inc., a national provider of hospice services, from 1996 to 2002, and he served as Chairman of VistaCare in 2003. From 1990 through 1995, Mr. Smith served as Chairman and Chief Executive Officer of Value Rx, Inc., which was then one of the country's largest pharmacy benefit management companies and, prior to that, served as vice president of operations for PCS Health Systems, also a pharmacy benefit management firm.- Barry M. Smith，他是董事会的成员（自2014年以来）。他目前任职董事会的薪酬委员会、提名及公司治理委员会、质量保证和合规委员会。他曾一直担任Magellan Health, Inc.（全国最大的行为健康服务供应商，一个领先的放射学收益管理服务、专业制药和处方管理服务的国家供应商）的主席兼首席执行官（2013年以来）。他曾创立VistaCare, Inc.（一个临终关怀服务的国家供应商），担任主席、总裁和首席执行官，也曾于2003年担任VistaCare公司的主席。1990年至1995年，他曾担任Value Rx, Inc.（全国最大的药房福利管理公司）的主席兼首席执行官。此前，他曾担任PCS Health Systems（药房福利管理公司）的运营副总裁。
- Barry M. Smith,most recently served as Chairman and Chief Executive Officer of Magellan Health, Inc. (NASDAQ: MGLN), the nation's largest provider of behavioral health services and a leading national provider of radiology benefit management services, specialty pharmacy and prescription benefit management services, since 2013. He retired from Magellan at the end of 2019. He founded and served as Chairman, President and Chief Executive Officer of VistaCare, Inc., a national provider of hospice services, from 1996 to 2002, and he served as Chairman of VistaCare in 2003. From 1990 through 1995, Mr. Smith served as Chairman and Chief Executive Officer of Value Rx, Inc., which was then one of the country's largest pharmacy benefit management companies and, prior to that, served as vice president of operations for PCS Health Systems, also a pharmacy benefit management firm.